|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. The Lancet. 379:1245–1255. View Article : Google Scholar
|
|
3
|
Omyla-Staszewska J and Deptala A:
Effective therapeutic management of hepatocellular carcinoma-on the
basis of a clinical case. Contemp Oncol. 16:60–63. 2012.
|
|
4
|
Song DS, Nam SW, Bae SH, Kim JD, Jang JW,
Song MJ, Lee SW, Kim HY, Lee YJ, Chun HJ, et al: Outcome of
transarterial chemoembolization-based multi-modal treatment in
patients with unresectable hepatocellular carcinoma. World J
Gastroenterol. 21:2395–2404. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang YX, De Baere T, Idee JM and Ballet S:
Transcatheter embolization therapy in liver cancer: An update of
clinical evidences. Chin J Cancer Res. 27:96–121. 2015.PubMed/NCBI
|
|
6
|
Lo CM, Ngan H, Tso WK, Liu CL, Lam CM,
Poon RT, Fan ST and Wong J: Randomized controlled trial of
transarterial lipiodol chemoembolization for unresectable
hepatocellular carcinoma. Hepatology. 35:1164–1171. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pecot CV, Calin GA, Coleman RL,
Lopez-Berestein G and Sood AK: RNA interference in the clinic:
Challenges and future directions. Nat Rev Cancer. 11:59–67. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sharma P and Allison JP: The future of
immune checkpoint therapy. Science. 348:56–61. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu Q, Yang Y, Tan X, Tao Z, Adah D, Yu S,
Lu J, Zhao S, Qin L, Qin L and Chen X: Plasmodium parasite as an
effective hepatocellular carcinoma antigen glypican-3 delivery
vector. Oncotarget. 8:24785–24796. 2017.PubMed/NCBI
|
|
10
|
Rosenberg SA and Restifo NP: Adoptive cell
transfer as personalized immunotherapy for human cancer. Science.
348:62–68. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Doudna JA and Charpentier E: Genome
editing. The new frontier of genome engineering with CRISPR-Cas9.
Science. 346:12580962014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cong L, Ran FA, Cox D, Lin S, Barretto R,
Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA and Zhang F:
Multiplex genome engineering using CRISPR/Cas systems. Science.
339:819–823. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Eid A and Mahfouz MM: Genome editing: The
road of CRISPR/Cas9 from bench to clinic. Exp Mol Med. 48:e2652016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zucman-Rossi J, Villanueva A, Nault JC and
Llovet JM: Genetic landscape and biomarkers of hepatocellular
carcinoma. Gastroenterology. 149(1226–1239): e12242015.
|
|
15
|
Favaro E, Lord S, Harris AL and Buffa FM:
Gene expression and hypoxia in breast cancer. Genome Med. 3:1–12.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Unruh A, Ressel A, Mohamed HG, Johnson RS,
Nadrowitz R, Richter E, Katschinski DM and Wenger RH: The
hypoxia-inducible factor-1 alpha is a negative factor for tumor
therapy. Oncogene. 22:3213–3220. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kang MJ, Jung SA, Jung JM, Kim SE, Jung
HK, Kim TH, Shim KN, Yi SY, Yoo K and Moon IH: Associations between
single nucleotide polymorphisms of MMP2, VEGF, and HIF1A genes and
the risk of developing colorectal cancer. Anticancer Res.
31:575–584. 2011.PubMed/NCBI
|
|
18
|
Yang SL, Liu LP, Jiang JX, Xiong ZF, He QJ
and Wu C: The Correlation of Expression Levels of HIF-1α and HIF-2α
in hepatocellular carcinoma with capsular invasion, portal vein
tumor thrombi and patients' clinical outcome. Jpn J Clin Oncol.
44:159–167. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen M, Huang SL, Zhang XQ, Zhang B, Zhu
H, Yang VW and Zou XP: Reversal effects of pantoprazole on
multidrug resistance in human gastric adenocarcinoma cells by
down-regulating the V-ATPases/mTOR/HIF-1α/P-gp and MRP1 signaling
pathway in vitro and in vivo. J Cell Biochem. 113:2474–2487. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jia ZZ, Jiang GM and Feng YL: Serum
HIF-1alpha and VEGF levels pre- and post-TACE in patients with
primary liver cancer. Chin Med Sci J. 26:158–162. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu K, Min XL, Peng J, Yang K, Yang L and
Zhang XM: The Changes of HIF-1alpha and VEGF expression after TACE
in patients with hepatocellular carcinoma. J Clin Med Res.
8:297–302. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu S, Yao Y, Xiao H, Li J, Liu Q, Yang Y,
Adah D, Lu J, Zhao S, Qin L, et al: Simultaneous knockout of CXCR4
and CCR5 genes in CD4+ T cells via CRISPR/Cas9 confers resistance
to both X4- and R5-tropic human immunodeficiency virus type 1
infection. Hum Gene Ther. 29:51–67. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang S, Zeng X, Liu Y, Liang C, Zhang H,
Liu C, Du W and Zhang Z: Construction and characterization of a
PDCD5 recombinant lentivirus vector and its expression in tumor
cells. Oncol Rep. 28:91–98. 2012.PubMed/NCBI
|
|
24
|
Lopez-Sanchez LM, Jimenez C, Valverde A,
Hernandez V, Peñarando J, Martinez A, Lopez-Pedrera C,
Muñoz-Castañeda JR, De la Haba-Rodríguez JR, Aranda E, et al:
CoCl2, a mimic of hypoxia, induces formation of polyploid giant
cells with stem characteristics in colon cancer. PLoS One.
9:e991432014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang YB, Wang X, Meister EA, Gong KR, Yan
SC, Lu GW, Ji XM and Shao G: The effects of CoCl2 on HIF-1α protein
under experimental conditions of autoprogressive hypoxia using
mouse models. Int J Mol Sci. 15:10999–11012. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ma SH, Chen GG, Yip J and Lai PB:
Therapeutic effect of alpha-fetoprotein promoter-mediated tBid and
chemotherapeutic agents on orthotopic liver tumor in mice. Gene
Ther. 17:905–912. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ikeda M, Maeda S, Shibata J, Muta R,
Ashihara H, Tanaka M, Fujiyama S and Tomita K: Transcatheter
arterial chemotherapy with and without embolization in patients
with hepatocellular carcinoma. Oncology. 66:24–31. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Soeda A, Park M, Lee D, Mintz A,
Androutsellis-Theotokis A, McKay RD, Engh J, Iwama T, Kunisada T,
Kassam AB, et al: Hypoxia promotes expansion of the CD133-positive
glioma stem cells through activation of HIF-1alpha. Oncogene.
28:3949–3959. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu K, Min XL, Peng J, Yang K, Yang L and
Zhang XM: The changes of HIF-1α and VEGF expression after TACE in
patients with hepatocellular carcinoma. J Clin Med Res. 8:297–302.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen CS, Zhao Q, Qian S, Li HL, Guo CY,
Zhang W, Yan ZP, Liu R and Wang JH: Ultrasound-guided RNA
interference targeting HIF-1 alpha improves the effects of
transarterial chemoembolization in rat liver tumors. Onco Targets
Ther. 8:3539–3548. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen C, Wang J, Liu R and Qian S: RNA
interference of hypoxia-inducible factor-1 alpha improves the
effects of transcatheter arterial embolization in rat liver tumors.
Tumour Biol. 33:1095–1103. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shan JZ, Xuan YY, Zhang Q and Huang JJ:
Ursolic acid sensitized colon cancer cells to chemotherapy under
hypoxia by inhibiting MDR1 through HIF-1α. J Zhejiang Univ Sci B.
17:672–682. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang M, Zhao X, Zhu D, Liu T, Liang X, Liu
F, Zhang Y, Dong X and Sun B: HIF-1α promoted vasculogenic mimicry
formation in hepatocellular carcinoma through LOXL2 up-regulation
in hypoxic tumor microenvironment. J Exp Clin Cancer Res.
36:602017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sanchez-Rivera FJ and Jacks T:
Applications of the CRISPR-Cas9 system in cancer biology. Nat Rev
Cancer. 15:387–395. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhen S, Hua L, Liu YH, Gao LC, Fu J, Wan
DY, Dong LH, Song HF and Gao X: Harnessing the clustered regularly
interspaced short palindromic repeat (CRISPR)/CRISPR-associated
Cas9 system to disrupt the hepatitis B virus. Gene Therapy.
22:404–412. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Seeger C and Ji AS: Complete spectrum of
CRISPR/Cas9-induced mutations on HBV cccDNA. Mol Ther.
24:1258–1266. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
White MK and Kamel K: CRISPR/Cas9 and
cancer targets: Future possibilities and present challenges.
Oncotarget. 7:12305–12317. 2016. View Article : Google Scholar : PubMed/NCBI
|
